Over the 12 years that followed licensing of the first TNF inhibitor for an inflammatory disease, research has shown that, for most patients, infliximab effectively treats signs and symptoms, provides rapid and prolonged suppression of inflammation and may prevent long-term disease progression in RA, AS and PsA. The gene discussed is TNF; the disease is rheumatoid arthritis.